“Even though drugs like tirzepatide and semaglutide work really well—better than anything we have ever seen—we still have people who don't respond to them,” said Dr. Aronne.

Adults with obesity who used tirzepatide for 72 weeks after lifestyle intervention or continuously for 88 weeks achieved a mean weight loss of 26%, according to topline results from two SURMOUNT ...

The current trial included a higher percentage of men (35%) than previous trials, especially when compared with the STEP trials involving persons without diabetes, in which 19 to 26% of the ...

The trial randomized 751 participants across the U.S. and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of tirzepatide (10 mg or 15 mg) or Wegovy (1.7 mg or 2.4 mg).

Researchers collected data from the five SURPASS trials, which assessed the effects of tirzepatide among people with type 2 diabetes. Tirzepatide was compared with placebo in SURPASS-1 and SURPASS ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

In the latter trial, 15 mg of tirzepatide reduced A1C by 2.59% and body weight by 10.9 kg (11.6%) from baseline. Furthermore, when receiving the highest dose, 62.4% of SURPASS-5 trial participants ...

Tirzepatide, which is sold under the brand names Mounjaro and Zepbound – which treat diabetes and weight loss, respectively – leads to more weight loss than semaglutide, new research has shown ...

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. First head-to-head trial compares tirzepatide and semaglutide - Results are in ...